Microsaic Systems Rises on New Mass Spectrometry Technology

By Anthony O. Goriainoff

Microsaic Systems PLC shares rose Friday after the company announced it had developed mass spectrometry technology for the online production of biotherapeutic drugs such as vaccines and cancer treatments.

Shares rose 0.05 pence, or 22%, to 0.28 pence by 0705 GMT.

The British tech company said this technology can analyze small and large molecules at the same time, and will connect end-user manufacturing processes in the second half of 2021.

The company said this technology enables constant monitoring of production processes to ensure high quality biological production input.

“In just a short amount of time, we have demonstrated and deployed an efficient method of automated production scaling to get drugs and vaccines to market quickly, at lower production costs and without human intervention, while maintaining consistently high quality,” said CEO Glenn Tracey said.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

Comments are closed.